Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Immatics N.V.

IMTXNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 4:15 PM ESTFiling CIK 1809196Accession 0001104659-26-128332
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Immatics N.V.
Company CIK
0001809196
Street
PAUL EHRLICH-STRASSE 15
City
Tubingen
State / country code
2M
Postal code
72076

Statement details

Amendment number
7
Security class
Ordinary Shares, nominal value EUR 0.01 per share
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
Baker Bros. Advisors LP
Citizenship / organization
DE
Reporting person type
IA · PN
Aggregate amount owned
4,256,682.00
Percent of class
2.8
Sole voting power
4,256,682.00
Shared voting power
0.00
Sole dispositive power
4,256,682.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 2

Name
Baker Bros. Advisors (GP) LLC
Citizenship / organization
DE
Reporting person type
HC · OO
Aggregate amount owned
4,256,682.00
Percent of class
2.8
Sole voting power
4,256,682.00
Shared voting power
0.00
Sole dispositive power
4,256,682.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 3

Name
Julian C. Baker
Citizenship / organization
X1
Reporting person type
HC · IN
Aggregate amount owned
4,256,682.00
Percent of class
2.8
Sole voting power
4,256,682.00
Shared voting power
0.00
Sole dispositive power
4,256,682.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 4

Name
Felix J. Baker
Citizenship / organization
X1
Reporting person type
HC · IN
Aggregate amount owned
4,256,682.00
Percent of class
2.8
Sole voting power
4,256,682.00
Shared voting power
0.00
Sole dispositive power
4,256,682.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Item 1

Issuer

Immatics N.V.

Principal executive office address

PAUL EHRLICH-STRASSE 15 Tubingen, 2M, 72076

Item 2

Citizenship

The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

Filing person

This Amendment No. 7 to Schedule 13G amends the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the "Adviser"), Baker Bros. Advisors (GP) LLC (the "Adviser GP"), Julian C. Baker and Felix J. Baker (collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect. This Amendment No. 7 is being filed jointly by the Reporting Persons.

Principal business or residence address

The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 10014 (212) 339-5690

Item 3

Not applicable indication

N

Type of filing person

IA · HC

Item 4

Percent of class

The information in Item 11 of each of the cover pages to this Amendment No. 7 is incorporated herein by reference. The percentage of beneficial ownership for each of the Reporting Persons reported herein is based on 152,266,773 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's 6-K filed with the Securities and Exchange Commission ("SEC") on November 10, 2026.

Amount beneficially owned

Items 5 through 9 of each of the cover pages to this Amendment No. 7 are incorporated herein by reference. Set forth below is the aggregate number of ordinary shares ("Common Stock") of Immatics N.V. (the "Issuer") directly held in the aggregate by Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") which may be deemed to be indirectly beneficially owned by the Reporting Persons. The Reporting Persons beneficially own 4,256,682 shares of Common Stock directly held by the Funds. Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds' respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments. The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

Sole voting power

The Reporting Persons have sole power to vote or direct the vote of 4,256,682 shares of Common Stock directly held by the Funds.

Shared voting power

0

Sole dispositive power

The Reporting Persons have sole power to dispose or direct the disposition of 4,256,682 shares of Common Stock directly held by the Funds.

Shared dispositive power

0

Item 5

Not applicable indication

N

Ownership of 5% or less

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

N

Subsidiaries

The information in Item 4 is incorporated herein by reference.

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature 1

Reporting person
Baker Bros. Advisors LP
Signed
/s/ Scott L. Lessing
Title
Scott L. Lessing/ President By: Baker Bros. Advisors (GP) LLC, its general partner
Date
11/16/2026

Signature 2

Reporting person
Baker Bros. Advisors (GP) LLC
Signed
/s/ Scott L. Lessing
Title
Scott L. Lessing/ President
Date
11/16/2026

Signature 3

Reporting person
Julian C. Baker
Signed
/s/ Julian C. Baker
Title
Julian C. Baker
Date
11/16/2026

Signature 4

Reporting person
Felix J. Baker
Signed
/s/ Felix J. Baker
Title
Felix J. Baker
Date
11/16/2026

Company context

Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.

Current securities

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A - filed by MONTANOVA CAPITAL, LLC regarding Immatics N.V.Nov 13, 2026
  2. 6-K filingNov 10, 2026
  3. 6-K filingOct 26, 2026
  4. 6-K filingOct 23, 2026
  5. 4 filingAug 27, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.